Announced acceptance and Priority Review by the United States Food and Drug Administration (FDA) of the new drug application (NDA) for troriluzole in all-genotype spinocerebellar ataxia; expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback